Genelux Corporation (GNLX) Research

Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.

Market snapshot

Symbol
GNLX
Price
$2.97
Day change
+4.04%
Market cap
$111.5M
P/E ratio
-3.03x
52-week range
2.29-8.535
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$17.33

Peer companies

  • AC Immune S.A. (ACIU)
  • Aldeyra Therapeutics, Inc. (ALDX)
  • Candel Therapeutics, Inc. (CADL)
  • Cellectis S.A. (CLLS)
  • Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
  • Alpha Tau Medical Ltd. (DRTS)
  • Lexeo Therapeutics, Inc. Common Stock (LXEO)
  • Lyell Immunopharma, Inc. (LYEL)

Recent insider activity

  • Pulisic Matthew — A-Award (278906 shares) on 2026-06-16
  • Groen Eric — A-Award (233957 shares) on 2026-06-16
  • Cappello Joseph — A-Award (174841 shares) on 2026-06-16
  • Tyree James L — A-Award (28409 shares) on 2026-06-16
  • Tyree James L — A-Award (31566 shares) on 2026-06-16

Open Genelux Corporation (GNLX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.